ACRS

NASDAQ Healthcare

Aclaris Therapeutics, Inc. - Common Stock

Biotechnology

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

๐Ÿ“Š Market Data
๐ŸŽฏ Investment Strategy Scores

ACRS scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 39/100โ–ผ -2
High dividend yield + low volatility
๐Ÿš€ Moon Shot 38/100โ–ฒ +16
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 6/100โ–ฒ +4
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 65/100โ–ผ -22
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (65/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿ”ช Falling Knife (6/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find ACRS in your text

Paste any article, transcript, or post โ€” the tool will extract ACRS and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.